Literature DB >> 1590986

Molecular approaches to analysis of X-linked immunodeficiencies.

M E Conley1.   

Abstract

Although the X-linked immunodeficiencies--X-linked agammaglobulinemia (XLA), X-linked severe combined immunodeficiency (XSCID), Wiskott-Aldrich syndrome (WAS), X-linked lymphoproliferative syndrome and X-linked hyper IgM syndrome--have been mapped to loci distributed throughout the X chromosome, they have several features in common that suggest that they might be members of a gene family: (i) all are maintained in the population at approximately the same gene frequency; (ii) expression of each defect is limited to the hematopoietic system; (iii) atypical forms of each disorder have been described; and (iv) obligate carriers of these disorders are normal by all immunologic criteria. The failure of carriers of XLA, XSCID, and WAS to show signs of their gene defects can be explained by the preferential use of the normal, nonmutant X as the active X in the cell lineages affected by the gene defects. These three disorders also share an additional feature; in boys with XLA, XSCID, or WAS there is asynchronous expression of cell surface markers of differentiation or activation. If some or all of the genes that are abnormal in the X-linked immunodeficiencies are members of a gene family, then isolation of one gene may lead to the others.

Entities:  

Mesh:

Year:  1992        PMID: 1590986     DOI: 10.1146/annurev.iy.10.040192.001243

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  26 in total

Review 1.  X-linked agammaglobulinemia.

Authors:  M E Conley; J Rohrer; Y Minegishi
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  B-cell-specific demethylation of BTK, the defective gene in X-linked agammaglobulinemia.

Authors:  O Parolini; J Rohrer; L H Shapiro; M E Conley
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

Review 3.  The biology of the human ligand for CD40.

Authors:  M K Spriggs; W C Fanslow; R J Armitage; J Belmont
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

Review 4.  Role of tyrosine kinases in lymphocyte activation: targets for drug intervention.

Authors:  J H Hanke; B A Pollok; P S Changelian
Journal:  Inflamm Res       Date:  1995-09       Impact factor: 4.575

Review 5.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

6.  Are patients with X-linked agammaglobulinemia at increased risk of developing acute lymphoblastic leukemia?

Authors:  Mary Ellen Conley
Journal:  J Clin Immunol       Date:  2015-01-29       Impact factor: 8.317

7.  Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease.

Authors:  M Vihinen; D Vetrie; H S Maniar; H D Ochs; Q Zhu; I Vorechovský; A D Webster; L D Notarangelo; L Nilsson; J M Sowadski
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Application of carrier testing to genetic counseling for X-linked agammaglobulinemia.

Authors:  R C Allen; R G Nachtman; H M Rosenblatt; J W Belmont
Journal:  Am J Hum Genet       Date:  1994-01       Impact factor: 11.025

9.  Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.

Authors:  Y Ohta; R N Haire; R T Litman; S M Fu; R P Nelson; J Kratz; S J Kornfeld; M de la Morena; R A Good; G W Litman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

10.  X-linked severe combined immunodeficiency syndrome: the first Korean case with gamma c chain gene mutation and subsequent genetic counseling.

Authors:  Eun-Kyeong Jo; Satoru Kumaki; Du Wei; Shigeru Tsuchiya; Hirokazu Kanegane; Chang-Hwa Song; Ha Young Noh; Young Ok Kim; So Yeon Kim; Hae Yul Chung; Yoon Ha Kim; Hoon Kook
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.